Skip to main content
S&P 5007,696.02+1.68%DOW53,299.35+2.92%NASDAQ25,806.01+1.71%BTC$80,353.00+3.61%ETH$2,423.32+5.73%GOLD$4,073.00+3.37%OIL$88.31-8.10%
Smart Investors Daily
SID Premium
IN

NASDAQ · INBX

Inhibrx Biosciences, Inc.

Healthcare · Biotechnology

$81.08

Up+$2.98 (+3.67%)

Updated Nov 4, 2026, 6:57 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.2B
P/E ratio
-8.2
Dividend yield
0.00%
52-week range
$57.30 – $155.29
Volume
600.52K
Avg. volume
370.47K

Price performance · INBX

INBX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

INBX closed at $81.08 after 21 trading sessions, down 13.20% for the selected period.

Last close
$81.08
Period change
-13.20%
Period low
$71.78
Period high
$98.19
Daily close
View OHLC price history
INBX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$71.16$83.00$71.16$81.08600.52K
Nov 2, 2026$72.45$73.49$70.87$72.16234.38K
Oct 30, 2026$72.04$73.03$66.80$71.78438.83K
Oct 29, 2026$73.75$75.715$71.75$73.65358.74K
Oct 28, 2026$94.55$96.785$69.2701$73.291.19M
Oct 27, 2026$88.52$99.8838$88.52$95.66374.22K
Oct 26, 2026$93.80$94.46$86.92$88.61251.18K
Oct 23, 2026$96.96$96.99$92.50$93.38176.22K
Oct 22, 2026$96.94$100.1978$94.04$97.10249.51K
Oct 21, 2026$98.10$99.82$93.002$98.19239.32K
Oct 20, 2026$89.07$96.50$88.99$95.30221.43K
Oct 19, 2026$90.43$92.98$88.21$89.79156.06K
Oct 16, 2026$89.83$90.72$87.725$89.83146.45K
Oct 15, 2026$87.60$91.68$87.202$90.50226.45K
Oct 14, 2026$86.23$87.355$83.61$85.26246.81K
Oct 13, 2026$90.11$92.455$85.795$87.08370.62K
Oct 12, 2026$94.03$96.10$90.00$90.53216.1K
Oct 9, 2026$92.70$95.81$92.70$95.0186.82K
Oct 8, 2026$93.14$93.28$90.15$92.76208.04K
Oct 7, 2026$92.02$96.7099$90.6601$93.36223.78K
Oct 6, 2026$95.52$96.9599$92.60$93.41169.45K

Latest INBX news

The latest Smart Investors Daily articles mentioning INBX.

Stock researchCompany · Overview

INBX research

Overview

Company profile and research snapshot.

Company profile

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$12.24
Implied upside
—
Analysts
6
INBX recent ratings
DateFirmRatingTarget
Aug 24, 2026HC Wainwright & Co.Buy—
Apr 8, 2026StifelBuy—
Aug 22, 2025JMP SecuritiesMarket Perform—
May 15, 2025JMP SecuritiesMarket Perform—
Mar 18, 2025Citizens Capital MarketsMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Inhibrx Biosciences (INBX) Stock Looks Hard To Pin Down At This Price

Inhibrx Biosciences has delivered a strong 1 year share price run, and that kind of move naturally raises the question of whether the current US$97.10 level still lines up with what its book value can support. With the stock now drawing more attention after recent biotech sector discussions, the key issue is how much of that optimism is already embedded in the balance sheet. The share price is up 69.5% over the past year, which puts real weight on whether the accounting value of Inhibrx...

Yahoo · Oct 21, 2026

Insiders Load Up on These 2 ‘Strong Buy’ Stocks — Should You Follow Their Footsteps?

Investors are always seeking some new sign, some signal that will indicate the right stock, and the right place or time to invest. They’ll chase after analyst forecasts, macro headlines, and earnings whispers – all the usual signs. But there’s one signal that really stands out: insider trading. The insiders are the company officers, the C-suite execs and Directors on the Board who have an inside view of the company’s workings. They’ve got firsthand knowledge of their companies’ operations and fi

Yahoo · Oct 14, 2026

Are Inhibrx Biosciences' (INBX) Global Data Reveals Reframing Its Late-Stage Pipeline Credibility?

Inhibrx Biosciences recently announced that it will present updated data on its clinical-stage candidates INBRX-106 and INBRX-109 from phase 2/3 and phase 2 studies in head and neck squamous cell carcinoma and conventional chondrosarcoma at major oncology and tumor society conferences in Europe, the US, and South Korea. This cluster of high-profile scientific presentations, with materials to be shared on the company’s investor website, highlights how Inhibrx is bringing its clinical data...

Yahoo · Oct 13, 2026

Inhibrx Announces Participation in Upcoming Scientific Conferences

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By